CN106496331B - FSH-Fc fusion protein and preparation method and application thereof - Google Patents

FSH-Fc fusion protein and preparation method and application thereof Download PDF

Info

Publication number
CN106496331B
CN106496331B CN201610982738.1A CN201610982738A CN106496331B CN 106496331 B CN106496331 B CN 106496331B CN 201610982738 A CN201610982738 A CN 201610982738A CN 106496331 B CN106496331 B CN 106496331B
Authority
CN
China
Prior art keywords
fsh
chain
fusion protein
seq
fck
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610982738.1A
Other languages
Chinese (zh)
Other versions
CN106496331A (en
Inventor
高新
刘蕴慧
杨懿
李宏杰
刘玉杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taize Huikang Biomedical Co ltd
Original Assignee
Beijing Zhiling Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Zhiling Biomedical Technology Co ltd filed Critical Beijing Zhiling Biomedical Technology Co ltd
Priority to CN201610982738.1A priority Critical patent/CN106496331B/en
Publication of CN106496331A publication Critical patent/CN106496331A/en
Application granted granted Critical
Publication of CN106496331B publication Critical patent/CN106496331B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention belongs to the field of human reproductive disease treatment and assisted reproduction, and relates to a novel long-acting gonadotropin (FSH) and a preparation method thereof, and application thereof in assisted reproduction, wherein the FSH fusion protein is folded into a stable heterodimer form under the double actions of non-covalent combination between an FSH α subunit and an FSH β subunit and a locking and buckling Fc chain locking structure.

Description

FSH-Fc fusion protein and preparation method and application thereof
Technical Field
The invention belongs to the field of human reproductive disease treatment and assisted reproduction. The present invention relates to gonadotropin growth hormone. More particularly, the present invention relates to a novel long-acting gonadotropin, a process for its preparation, and its use in assisted reproduction.
Background
FSH is a glycosylated protein synthesized and secreted by anterior pituitary basophilic cells, natural FSH consists of α and β subunits, of which the α subunit is identical to the α subunit of chorionic Hormone (HCG) secreted by the pituitary gland, and the β subunit has its specificity, which is the determining factor for the bioactivity of FSH.it is known that the α subunit of FSH consists of 92-96 amino acids, the β subunit consists of 109-115 amino acids, the correct higher structure between the two subunits is maintained by internal disulfide bonds, and in addition N-glycosylation has a greater influence on the formation of the correct higher structure, FSLH is also strongly associated with the formation of the correct higher structure, FSH is mainly associated with FSLH receptor through the C-terminal of β subunit, FSLH produces two signaling effects, one is an activating aromatase, the other effect is to induce the production of the receptor for luteinizing Hormone, and the cell receptor for the ovarian Follicle Stimulating Hormone (FSLH) and the ovarian Follicle Stimulating Hormone secretion, thus the ovarian Follicle Stimulating Hormone and ovarian Follicle Stimulating Hormone, which are the combined with the ovarian growth promoting action of ovarian Follicle Stimulating Hormone in vivo, Stimulating Hormone, thus the ovarian Follicle Stimulating Hormone, Stimulating Hormone, Stimulating Hormone, Stimulating Hormone, Stimulating Hormone.
FSH can be isolated from pituitary or urine (EP322, 438) or prepared recombinantly (US5,639, 640, US5,156, 957, US4,923, 805, US4,840, 896, EP211,894). The purity of the recombinant human FSH is better than that of the extracted FSH, the curative effect of the recombinant human FSH is not greatly different from that of the extracted FSH, but both types of FSH need to be continuously administrated for 8-10 days to stimulate the follicular development of women, and the FSH is subcutaneously injected for at least 1 time every day to bring much inconvenience and pain to patients. Long acting recombinant FSH is one direction to solve these problems.
The current design of a corresponding product (elonva) developed and marketed in 2010 by merck, germany, which has the bioactivity of natural FSH and a half-life of 69h in humans, but due to the problems of immunogenicity, etc., the clinical administration scheme is changed to one week for the first administration and then to 3 days for continuous administration, i.e., the design of long-acting FSH still faces great difficulties and needs to be improved.
Fusion of FSH with albumin or Fc fragment of IgG is a common technique for increasing the in vivo half-life of active proteinsThe patent publication US0, 186,662 discloses that the half-life in the rat body is prolonged to 60 hours by constructing homo-and heterodimers of FSH-Fc fusion protein, while the specific activity is also improved, but it is difficult to completely separate the homo-and heterodimers of the by-products FSH α or FSH β from the target product FSH αβ heterodimer when recombinant FSH is prepared in this design, unless a purification tag such as HIS is additionally introduced, and the introduction of the purification tag limits the application of clinical treatment2The homodimer of (a) and thus the co-product interference facing homodimer is also required in constructing recombinant expression cell lines and purifying products, making the quality control of drugs more challenging.
The invention aims to provide an improved FSH-Fc fusion protein and a preparation method thereof, so as to obtain a long-acting heterodimer FSH-Fc fusion protein with the activity and uniform quality.
Disclosure of Invention
The inventive idea and principle of the present invention is that referring to the characteristic that the natural FSH structure is fused between the α and β subunits via non-covalent tight linkage to form heterodimers, the different single-chain Fc fragments are generated by different site-directed mutagenesis of certain amino acids on the binding surface of the natural Fc duplex, such that the amino acids in the CH3domain on one Fc chain are mutated to amino acids with small side chains, forming a "padlock" structure, and the corresponding amino acids on the other Fc chain are mutated to amino acids with large side chains, forming a "padlock" structure, which results in dimerization of two heteromonohol fragments, which is more prone to form heterodimers, thus the stability of the fusion between the heteromono Fc fragments is achieved by direct Fc-subunit fusion of the FSH α and β subunits via the non-covalent tight linkage, or by direct Fc-linker fusion of the natural FSH subunits with the N-Fc-linker "(i-Fc-linker) is directly fused to the N-Fc-subunit of the FSH subunit, i chain-Fc-linker-Fc-linker-Fc-linker-Fc-linker-Fc-linker-molecule, which is directly fused to form a loop-Fc-loop-Fc-loop-Fc-dimerization-protein under the same-dimerization-induced by a direct-dimerization process, which is directly-dimerization-induced by direct-dimerization-linking process, which is directly under the same-induced by direct.
The greatest difference between the present invention and the FSH-Fc fusion proteins of the prior art (US20050186662 and CN201210476665) is that FSH α and β subunits are fused to the N-terminus of the "padlock" and "padlock" Fc chains, respectively, or vice versa.in the prior art, the non-covalent binding dimerization between the α and β subunits of FSH is not combined with the Fc "locker" dimerization.the principle of the present invention is based on, on one hand, the CH3 structural design concept of "knob-int-holes" for the heavy chain ligation.Ridgway JB, Presta LG, Carp.Protein Eng.1996 Jul; 9 latch 7: 21. the knob-interlocking chains are incorporated herein by reference. the design of knob-button antibodies in particular in the context of heavy chains which, specifically, the heavy chain of antibodies, which form a heavy chain heterodimers with a smaller than the CH3, or which forms a heavy chain heterodimers with a side chains which are formed by the reverse side chain binding of the amino acid sequence of the CH3, or by the reverse side chain of the amino acid sequence of the CH-int-linker peptide.
In general, when bispecific antibodies are prepared using recombinant expression systems, by direct co-transfection of antibody A and antibody B genes, the proportion of spontaneously formed heterodimers AB in the expression product is less than 25%, whereas the proportion of AB heterodimers produced by the CH3 mutation is increased to more than 50%. To further increase the heterodimer ratio, the heterodimer ratio obtained by transiently transfected cells can be increased to 90% by optimizing the transfection-encoding DNA ratio, but in stably transfected cells, it is difficult to obtain a heterodimeric bispecific antibody of more than 50%. In industrial production, it is often necessary to use a stably expressing cell line to produce a recombinant antibody. Therefore, in the preparation of bispecific antibodies, additional mutations need to be introduced in the Fab fragment to increase heterodimer stability (progression in overlapping the chain association assay in biphenically modified IgG antibodies. Klein C et al, MAbs.2012; 4(6): 653-63.).
In the present invention, since there is a natural non-covalent tight association between the FSH- α subunit and the FSH- β subunit, and specific interaction between them promotes β 1 β heterodimerization, the α subunit of FSH is fused directly or indirectly via a linking element to the N-terminus of the "padlock Fc" chain, while the β subunit of FSH is fused directly or indirectly via a linking element to the N-terminus of the "padlock Fc" chain, or vice versa, the α subunit of FSH is fused directly or indirectly via a linking element to the N-terminus of the "padlock Fc" chain, while the β subunit of FSH is fused directly or indirectly via a linking element to the N-terminus of the "padlock Fc" chain, so that molecular interactions exist that stabilize the heterodimer structure between the N-terminal N- α subunit of the fusion protein and the FSH- β subunit, between the C-terminal "padlock" Fc chain and the "Fc chain fragment of the" Fc chain, under both interactions, the structural stability of FSH α -84-FSH β -Fck is improved, the stability of the FSH- β -Fck dimer is improved when the FSH-8225-25-b-t-.
In one aspect, the present invention provides a long-acting FSH fusion protein, said FSH fusion protein comprising two different peptide chains, one of which is FSH α subunit directly or indirectly linked to peptide chain FSH α -Fch formed at the N-terminus of the padlock Fc chain (Fch) via a linking element, the other of which is FSH β subunit directly or indirectly linked to FSH β -fck formed at the N-terminus of the padlock Fc chain (Fck) via a linking element, the two peptide chains, i.e. FSH α -Fch and FSH β -Fck, fold into a stable heterodimer in the form of FSH α -Fch-FSH β -Fck under the dual action between the non-covalent binding between the FSH α subunit and the FSH β subunit and the latch structure on the padlock Fc chain and the padlock Fc chain CH 3.
Or vice versa, in the long-acting FSH fusion protein of the present invention, one of the FSH α subunits is directly or indirectly linked to the peptide chain FSH α -Fck formed at the N-terminus of the buckled Fc chain (Fck) via a linking element, and the other is the peptide chain FSH β -fch formed at the N-terminus of the padlock Fc (fch) fragment via a FSH β subunit which is also linked to the N-terminus of the padlock Fc (fch) fragment via a linking element, so as to form another stable form of heterodimer FSH α -Fck-FSH β -Fch under the dual actions of the above-mentioned non-covalent binding action and padlock structure.
The FSH in the present invention is mammalian FSH, preferably human FSH.
The padlock Fc chain has an amino acid sequence shown in SEQ ID NO. 1. Or the padlock Fc chain comprises an amino acid sequence obtained by deleting, adding or substituting 1, 2 or 3 residues on SEQ ID NO. 1.
The button Fc chain has an amino acid sequence shown in SEQ ID NO. 2. Or the buckled Fc chain comprises an amino acid sequence obtained by deleting, adding or substituting 1, 2 or 3 residues on SEQ ID NO. 2.
The peptide chain FSH α -Fch has an amino acid sequence shown in SEQ ID NO.3, or an amino acid sequence obtained by deleting, adding or substituting 1, 2 or 3 residues on the SEQ ID NO. 3.
The peptide chain FSH β -Fck has an amino acid sequence shown in SEQ ID NO.4 or an amino acid sequence obtained by deleting, adding or substituting 1, 2 or 3 residues on the SEQ ID NO. 4.
In a specific embodiment of the invention, the long-acting FSH fusion protein comprises two different peptide chains FSH α -Fch and FSH β -Fck, wherein said FSH α -Fch has the amino acid sequence shown in SEQ ID No.3, and said FSH β -Fck has the amino acid sequence shown in SEQ ID No. 4.
The present invention also provides a vector comprising a cDNA encoding the peptide chain FSH α -Fch. in a specific embodiment of the present invention, the peptide chain FSH α -Fch has the amino acid sequence shown in SEQ ID NO. 3.
The present invention also provides a vector comprising a cDNA encoding the peptide chain FSH α -Fck in a specific embodiment of the present invention, the peptide chain FSH β -Fck has the amino acid sequence shown in SEQ ID NO. 4.
The invention also provides a vector which contains the cDNA coding SEQ ID NO.3 and the cDNA coding SEQ ID NO. 4. By expressing the FSH fusion protein in mammalian cells such as NS0 cells, CHO cells, HEK293 cells and the like, the invention realizes the aim of prolonging the in vivo half-life of FSH on the premise of keeping the bioactivity of FSH, has higher purity of an expression product, is easy to prepare, has more feasibility in a production process, and further provides a method which can reduce the administration frequency and still can play the therapeutic role of FSH in reproduction-related diseases.
In another aspect, the invention provides the use of the long-acting FSH fusion protein for the preparation of a medicament for the treatment of polycystic ovary syndrome or other anovulatory disease or disorder.
In another aspect, the invention provides the use of the long-acting FSH fusion protein for the preparation of a pro-ovarian hyperstimulation for use in assisted reproductive techniques.
In another aspect, the present invention provides a method for preparing a long-acting FSH fusion protein, comprising (1) synthesizing two different peptide chain-encoding cDNA sequences, one of which is peptide chain FSH α -Fch in which FSH α subunit is directly or indirectly linked to the N-terminus of a padlock Fc chain (Fch) through a linking element, and the other of which is peptide chain FSH β -Fck in which FSH β subunit is directly or indirectly linked to the N-terminus of a padlock Fc chain (Fck) through a linking element, (2) introducing the cDNA sequences encoding peptide chain FSH α -Fch and FSH β -Fck into a mammalian expression vector in an enzyme-cleaved linkage manner to obtain a recombinant double expression vector, and (3) transforming mammalian cells with the recombinant double expression vector obtained in step (2), and recovering and purifying the obtained FSH fusion protein.
The FSH-Fc fusion protein of the present invention can be purified from host cells by standard experimental means. Including, but not limited to, affinity purification with protein a.
Fc in the context of the present invention refers to the CH2 and CH3 fragments of the constant regions of human immunoglobulin chains, particularly the constant regions of immunoglobulin heavy chains. The Fc region of a natural human immunoglobulin varies from individual to individual with respect to amino acid differences. The human immunoglobulin Fc of the present invention also includes all changes to the amino acids of the native human immunoglobulin Fc sequence, including, but not limited to, changes to certain amino acids local to the Fc region, such as mutations including certain amino acid positions in the hinge region, certain amino acid mutations that reduce immune function, or other nonsense mutations.
In a particular embodiment, the human immunoglobulin Fc used in the present invention comprises at least one immunoglobulin hinge region, a CH2 domain and a CH3domain, in particular a mutant of human IgG4 Fc.
Mammalian host cells to which the present invention relates include, but are not limited to, CHO, HEK 293. The host cell may also be a yeast or prokaryotic cell such as e.coli.
Therefore, the present invention provides a method for increasing the half-life of FSH in vivo and facilitating the preparation of FSH-FC fusion proteins, while maintaining the bioactivity of FSH.
Drawings
FIG. 1 is a schematic diagram of a heterodimer of FSH α -Fch-FSH β -Fck fusion protein, subunit 1.α, subunit 2.β, fragment 3.IgGCH2, variant fragment 4. padlock IgG CH3, and variant fragment 5. padlock IgG CH 3.
FIG. 2 is a graph showing the results of the determination of the biological activity of FSH α -Fch-FSH β -Fck.
Examples
Example 1 construction of FSH α -Fch-FSH β -Fck heterodimer expression plasmid
Coding DNA sequences of FSH α -Fch (SEQ ID NO:3) and FSH β -Fck (SEQ ID NO:4) were synthesized based on the amino acid sequence of FSH α subunit (Gene bank No. NP-000726.1), human FSH β subunit amino acid sequence (Gene bank No. NP-000501.1), and the amino acid sequence of the latticed Fc chain shown in SEQ ID NO:1 (containing T148S, L150A, Y189V mutations, forming a smaller side chain structure) and the amino acid sequence of the latticed Fc chain shown in SEQ ID NO:2 (containing T148W mutations, forming a larger side chain structure), respectively, and the coding DNA sequences of FSH α -Fch (SEQ ID NO:3) and FSH β -Fck (SEQ ID NO:4) were introduced with restriction endonuclease SapI at the upstream and downstream of the coding sequences, respectively.
After the coding DNA is synthesized, FSH α -Fch is inserted into an expression vector pQKPX1 by utilizing a SapI restriction enzyme cutting site to generate a pQKPX1- α plasmid, FSH β -Fck is inserted into a pQKPX2 vector, an FSH β -Fck expression element in the pQKPX2 vector is cut off by utilizing NotI and PvuI restriction enzyme cutting sites and is inserted into a pQKPX1- α plasmid to generate a double expression plasmid pQKPX- αβ.
The successfully constructed double expression plasmid pQKPX- αβ was taken and digested with PvuI restriction enzyme, the digested product was separated and purified by 0.8% agarose electrophoresis, and a linearized DNA fragment of about 11000bp in size was recovered and prepared for transfection of CHO-K1 cells.
Example 2 expression and purification of FSH α -Fch-FSH β -Fck heterodimer protein
2.1 Stable expression of FSH α -Fch-FSH β -Fck heterodimer
CHO-K1(ATCC, CCL-61) cells acclimated to serum-free medium at 5X 106Inoculating cells/ml into 30ml CD-CHO culture medium, and culturing for 24hr until cell density reaches 1-2 × 106cells/ml. The cell suspension was centrifuged at 800rpm for 5min, the supernatant was discarded, the cells were washed 2 times with 50ml of CD CHO medium, the supernatant was discarded, and the cell suspension was resuspended in 1ml of CD CHO medium. Cells and plasmids were arranged at 1X 107cell: 40. mu.g DNA, setting electroporation transfection parameters: the voltage is 300V; capacitor 900 muAnd F, performing electric pulse, transferring the transfected cells into 100ml of CD-CHO culture medium, and subpackaging the cells into 10 96-well plates with each plate hole being 100 mu L. After 24 hours, 100 mul of MSX working solution is respectively added for pressure screening. After the cell plate was cultured for 3 weeks, cell clones were formed in the plate wells. Selecting the monoclonal cells with good separation degree, transferring the cells to a 24-pore plate and a 6-pore plate in sequence for amplification culture, quantitatively detecting culture supernatant by using an HPLC-ProteinA chromatographic column, selecting 10 cell clones with higher expression level for further culture in a shake flask, and carrying out non-reduction SDS-PAGE electrophoresis detection on the culture supernatant.
2.2 purification of the FSH α -Fch-FSH β -Fck heterodimer protein
SDS-PAGE electrophoresis and western-blotting detection show that the main components in the culture supernatant are heterodimers and partial degradation products, and homodimers can hardly be detected or a very small amount of homodimers can be contained. Purification can therefore be carried out by proteinA affinity chromatography in combination with ion exchange. The cell supernatant was centrifuged, and the supernatant was collected and filtered through a 0.22 μm filter to prepare a sample. The Protein A affinity chromatography column was equilibrated with 20mM PB buffer containing 50mM NaCl at pH7.0, and the filtered sample was applied, rinsed with the equilibration buffer after the application, and then eluted with 0.1M citric acid at pH3.0 to remove the target Protein. After one-step purification, HPLC results show that the purity reaches more than 95%. Further purifying by anion exchange, using Hitrap Q HP ion exchange column, loading after balancing with 20mM PB buffer solution, eluting with 20mM PB buffer solution containing 1M NaCl, and detecting the purity of the eluted target protein by HPLC to reach 99%.
Example 3 detection of the biological Activity of FSH α -Fch-FSH β -Fck heterodimers
The biological activity of FSH recombinant protein is determined by adopting a rat ovary weight increasing method according to the pharmacopoeia of China, the HCG is used for assisting a tested FSH medicament, immature female rats of 21 days old are stimulated, ovarian follicle growth and egg cell generation are triggered, and the biological activity of the tested medicament can be clearly evaluated by measuring the weight of ovaries at the end of administration.
Example 4 determination of half-life of FSH α -Fch-FSH β -Fck heterodimers
According to 0.1mg/kg body weight, a single administration of FSH α -Fch-FSH β -Fck heterodimer fusion protein is performed subcutaneously to macaques, 0.6mL of venous blood is collected at 2, 4,8 and 12hr, 2, 3, 4,8, 10 and 12day after the administration, FSH content in samples is determined by sandwich ELISA, PK parameters of FSH in macaques blood serum are calculated by WinNonlin software, and the results are shown in the following table 1. pharmacokinetic parameters show that the FSH α -Fch-FSH β -Fck heterodimer fusion protein of the invention has higher area under the drug time curve, and the half-life is calculated to be about 248 hours, while the half-life of simultaneously determined fruinafine is 17.3 hours, and the half-life of the FSH α -Fch-FSH β -Fck heterodimer is 14 times that of the latter (table 1).
TABLE 1 pharmacokinetic parameters of FSH α -Fch-FSH β -Fck heterodimer fusion proteins
Figure BDA0001147737190000071
Figure BDA0001147737190000081
Sequence listing
<110> Beijing Qikang Xingheng biological medicine science and technology Limited
<120> novel FSH-Fc fusion protein, preparation method and application thereof
<130>
<160>4
<170>PatentIn version 3.5
<210>1
<211>229
<212>PRT
<213> Artificial sequence
<220>
<221> Padlock Fc chain Fch
<222>(1)..(229)
<400>1
Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu
1 5 10 15
Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
20 25 30
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
35 40 45
Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
50 55 60
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
65 70 75 80
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
85 90 95
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
100 105 110
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
115 120 125
Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
130 135 140
Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile
145 150 155 160
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
165 170 175
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Arg
180 185 190
Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys
195 200 205
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
210 215 220
Ser Leu Ser Leu Gly
225
<210>2
<211>229
<212>PRT
<213> Artificial sequence
<400>2
Ala Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu
1 5 10 15
Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
20 25 30
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
35 40 45
Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
50 55 60
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
65 70 75 80
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
85 90 95
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
100 105 110
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
115 120 125
Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
130 135 140
Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
145 150 155 160
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
165 170 175
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
180 185 190
Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys
195 200 205
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
210 215 220
Ser Leu Ser Leu Gly
225
<210>3
<211>336
<212>PRT
<213> Artificial sequence
<220>
<221> peptide chain FSH α -Fch
<222>(1)..(336)
<400>3
Ala Pro Asp Val Gln Asp Cys Pro Glu Cys Thr Leu Gln Glu Asn Pro
1 5 10 15
Phe Phe Ser Gln Pro Gly Ala Pro Ile Leu Gln Cys Met Gly Cys Cys
20 25 30
Phe Ser Arg Ala Tyr Pro Thr Pro Leu Arg Ser Lys Lys Thr Met Leu
35 40 45
Val Gln Lys Asn Val Thr Ser Glu Ser Thr Cys Cys Val Ala Lys Ser
50 55 60
Tyr Asn Arg Val Thr Val Met Gly Gly Phe Lys Val Glu Asn His Thr
65 70 75 80
Ala Cys His Cys Ser Thr Cys Tyr Tyr His Lys Ser Gly Gly Gly Gly
85 90 95
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly SerAla Glu Ser Lys Tyr
100 105 110
Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro
115 120 125
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
130 135 140
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp
145 150 155 160
Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
165 170 175
Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val
180 185 190
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
195 200 205
Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys
210 215 220
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
225 230 235 240
Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Ser
245 250 255
Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala ValGlu Trp Glu
260 265 270
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
275 280 285
Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Arg Leu Thr Val Asp Lys
290 295 300
Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu
305 310 315 320
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly
325 330 335
<210>4
<211>355
<212>PRT
<213> Artificial sequence
<220>
<221> peptide chain FSH β -Fck
<222>(1)..(355)
<400>4
Asn Ser Cys Glu Leu Thr Asn Ile Thr Ile Ala Ile Glu Lys Glu Glu
1 5 10 15
Cys Arg Phe Cys Ile Ser Ile Asn Thr Thr Trp Cys Ala Gly Tyr Cys
20 25 30
Tyr Thr Arg Asp Leu Val Tyr Lys Asp Pro Ala Arg Pro Lys Ile Gln
35 40 45
Lys Thr Cys Thr Phe Lys Glu Leu Val Tyr Glu Thr Val Arg Val Pro
50 55 60
Gly Cys Ala His His Ala Asp Ser Leu Tyr Thr Tyr Pro Val Ala Thr
65 70 75 80
Gln Cys His Cys Gly Lys Cys Asp Ser Asp Ser Thr Asp Cys Thr Val
85 90 95
Arg Gly Leu Gly Pro Ser Tyr Cys Ser Phe Gly Glu Met Lys Glu Gly
100 105 110
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Glu
115 120 125
Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
130 135 140
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
145 150 155 160
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
165 170 175
Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu
180 185 190
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr
195 200 205
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
210 215 220
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser
225 230 235 240
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
245 250 255
Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val
260 265 270
Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
275 280 285
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
290 295 300
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr
305 310 315 320
Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val
325 330 335
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
340 345 350
Ser Leu Gly
355

Claims (12)

1. A long-acting FSH fusion protein comprises two different peptide chains, wherein one peptide chain is FSH α -Fch formed by connecting an FSH α subunit to a locked Fc chain FchN end directly or indirectly through a linking element, the other peptide chain is FSH β -Fck formed by connecting an FSH β subunit to a locked Fc chain FckN end directly or indirectly through a linking element, and the peptide chains FSH α -Fch and FSH β -Fck are folded into a stable heterodimer in the form of FSH α -Fch-FSH β -Fck under the double actions of non-covalent combination between the FSH α subunit and the FSH β subunit and a locking structure on the locked Fc chain CH 3.
2. A long-acting FSH fusion protein comprises two different peptide chains, wherein one peptide chain is FSH α -Fck formed by connecting an FSH α subunit to an FckN end of a button Fc chain directly or indirectly through a linking element, the other peptide chain is FSH α -Fch formed by connecting an FSH β subunit directly or indirectly through a linking element to an N end of a padlock Fcfch fragment, and the peptide chains FSH α -Fck and FSH α -Fch are folded into a stable heterodimer in the form of FSH α -Fck-FSH β -Fch under the double effects of non-covalent combination between the FSH α subunit and the FSH β subunit and a lock structure on the padlock and the button Fc chain CH 3.
3. The long-acting FSH fusion protein of claim 1 or 2, wherein said FSH is human FSH.
4. The long-acting FSH fusion protein of any of claims 1 to 3, wherein said Fc is IgG4 Fc.
5. The long-acting FSH fusion protein of claim 4, wherein said padlock Fc chain Fch has T148S, L150A, Y189V mutations compared to wild-type IgG4 Fc; the buckled Fc chain Fck has a T148W mutation compared to wild-type IgG4 Fc.
6. The long-acting FSH fusion protein of claim 5 wherein the padlock Fc chain has an amino acid sequence as set forth in SEQ ID NO. 1 or by deletion, addition or substitution of 1, 2 or 3 residues in SEQ ID NO. 1; the button Fc chain has an amino acid sequence shown in SEQ ID NO. 2 or obtained by deleting, adding or substituting 1, 2 or 3 residues on the SEQ ID NO. 2.
7. The long-acting FSH fusion protein of claim 1, wherein said peptide chain FSH α -Fch has the amino acid sequence shown in SEQ ID No.3 or 1, 2 or 3 residue amino acid sequence deleted, added or substituted on SEQ ID No. 3.
8. The long-acting FSH fusion protein of claim 1, wherein said peptide chain FSH α -Fck has the amino acid sequence shown in SEQ ID No.4 or 1, 2 or 3 residue amino acid sequence deleted, added or substituted on SEQ ID No. 4.
9. The long-acting FSH fusion protein of claim 7 or 8 wherein the peptide chain FSH α -Fch has an amino acid sequence shown in SEQ ID NO.3 or 1, 2 or 3 residues deleted, added or substituted on SEQ ID NO.3 and the peptide chain FSH α -Fck has an amino acid sequence shown in SEQ ID NO.4 or 1, 2 or 3 residues deleted, added or substituted on SEQ ID NO. 4.
10. Use of a long-acting FSH fusion protein as claimed in any one of claims 1 to 9 in the manufacture of a medicament for the treatment of polycystic ovary syndrome or other anovulatory disease or disorder.
11. Use of a long acting FSH fusion protein as claimed in any one of claims 1 to 9 for the preparation of a pro-ovarian hyperstimulation for use in assisted reproductive techniques.
12. A method of preparing a long-acting FSH fusion protein according to any of claims 1 to 9.
CN201610982738.1A 2016-11-08 2016-11-08 FSH-Fc fusion protein and preparation method and application thereof Active CN106496331B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610982738.1A CN106496331B (en) 2016-11-08 2016-11-08 FSH-Fc fusion protein and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610982738.1A CN106496331B (en) 2016-11-08 2016-11-08 FSH-Fc fusion protein and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN106496331A CN106496331A (en) 2017-03-15
CN106496331B true CN106496331B (en) 2020-03-13

Family

ID=58323721

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610982738.1A Active CN106496331B (en) 2016-11-08 2016-11-08 FSH-Fc fusion protein and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN106496331B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108794634A (en) * 2017-05-03 2018-11-13 上海兴迪金生物技术有限公司 The long-acting human growth hormone (HGH) fusion protein and its preparation and use of recombination
CN107082815A (en) * 2017-06-28 2017-08-22 杭州皓阳生物技术有限公司 A kind of FSH HSA fusion proteins and preparation method thereof
CN107540748B (en) 2017-09-15 2020-07-14 北京伟杰信生物科技有限公司 Long-acting recombinant porcine FSH fusion protein and preparation method and application thereof
CN115975043A (en) * 2021-09-30 2023-04-18 宁波三生生物科技股份有限公司 Recombinant follicle stimulating hormone fusion protein

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993048A (en) * 2002-02-21 2007-07-04 惠氏公司 Follistatin domain containing proteins
CN103429619A (en) * 2011-03-17 2013-12-04 雷蒙特亚特特拉维夫大学有限公司 Bi- and monospecific, asymmetric antibodies and method of generating same
CN103539861A (en) * 2013-11-01 2014-01-29 广州诺新生物技术有限公司 Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc)
WO2015103928A1 (en) * 2014-01-08 2015-07-16 上海恒瑞医药有限公司 Il-15 heterogeneous dimer protein and uses thereof
WO2016001810A1 (en) * 2014-07-01 2016-01-07 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993048A (en) * 2002-02-21 2007-07-04 惠氏公司 Follistatin domain containing proteins
CN103429619A (en) * 2011-03-17 2013-12-04 雷蒙特亚特特拉维夫大学有限公司 Bi- and monospecific, asymmetric antibodies and method of generating same
CN103539861A (en) * 2013-11-01 2014-01-29 广州诺新生物技术有限公司 Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc)
WO2015103928A1 (en) * 2014-01-08 2015-07-16 上海恒瑞医药有限公司 Il-15 heterogeneous dimer protein and uses thereof
WO2016001810A1 (en) * 2014-07-01 2016-01-07 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof

Also Published As

Publication number Publication date
CN106496331A (en) 2017-03-15

Similar Documents

Publication Publication Date Title
JP6010148B2 (en) Antibody constant region variants
EP1641823B1 (en) Glp-1 analog fusion plroteins
JP5787446B2 (en) Antibody constant region variants
CN106496331B (en) FSH-Fc fusion protein and preparation method and application thereof
US9969786B2 (en) Trophic hormone fusion protein, preparation method and application thereof
EP4122951A1 (en) Interleukin-2 mutant and use thereof
KR20230141929A (en) Stabilization of fc-containing polypeptides
JPH07501698A (en) Bivalent specific heterodimer
KR20100074221A (en) Modified antibody constant region
WO2005040217B1 (en) Antibodies having a mutated amino acid residue at position 268 (ch2 region) in constant regions
US20230002466A1 (en) Engineered interleukin-2 receptor beta agonists
US20230287040A1 (en) Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
CN106008717B (en) Long-acting recombinant GLP-1 fusion protein and preparation method and application thereof
CN106957365B (en) Monoclonal antibody FnAb8 and application thereof
JP2016511275A (en) Growth hormone compounds
CN114591415B (en) GLP-1/GCG double receptor agonist polypeptide and fusion protein thereof
CN111217915B (en) GLP-1 analogue Fc fusion polypeptide and application thereof
CN106957364B (en) Monoclonal antibody FnAb12 and application thereof
WO2022089418A1 (en) Fusion protein of recombinant truncated flt3 ligand and human antibody fc
CN116948037A (en) Novel-structure long-acting follicle-stimulating hormone recombinant protein, and preparation and application thereof
CN117769564A (en) Fusion proteins, pharmaceutical compositions and therapeutic uses
CN118063624A (en) Recombinant human growth hormone fusion protein and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20181113

Address after: 102206 Room 1333, Floor 1, 33 Science Park Road, Huilongguan Town, Changping District, Beijing

Applicant after: Beijing Zhiling Biomedical Technology Co., Ltd.

Address before: 100850 Zhongguancun Biomedical Park B210, No. 5 Shangdi Development Road, Haidian District, Beijing

Applicant before: Beijing Kai Kang Biotechnology Co., Ltd.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210622

Address after: 266200 No.168 Ningdong Road, Chuangzhi New District, Jimo District, Qingdao City, Shandong Province

Patentee after: Shandong Taize Huikang biomedical Co.,Ltd.

Address before: 102206 Room 1333, Floor 1, 33 Science Park Road, Huilongguan Town, Changping District, Beijing

Patentee before: Beijing Zhiling Biomedical Technology Co.,Ltd.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 266200 No.168 Ningdong Road, Chuangzhi New District, Jimo District, Qingdao City, Shandong Province

Patentee after: Taize Huikang biomedical Co.,Ltd.

Address before: 266200 No.168 Ningdong Road, Chuangzhi New District, Jimo District, Qingdao City, Shandong Province

Patentee before: Shandong Taize Huikang biomedical Co.,Ltd.

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: FSH Fc fusion protein and its preparation method and Application

Effective date of registration: 20220511

Granted publication date: 20200313

Pledgee: Qingdao Jimo District Urban Investment Promotion Co.,Ltd.

Pledgor: Taize Huikang biomedical Co.,Ltd.

Registration number: Y2022980005408